Get the content you want anytime you want.

Healthcare professionals and thought leaders share their knowledge and insights on an array of infectious disease topics

Latest Videos

Battling Resistance to HIV Therapy: New Drugs in the Pipeline
Joseph Eron, MD, explains how some individuals acquire resistance to HIV therapy and discusses new drugs in the pipeline that are effective against resistant virus.
<i>Pseudomonas</i> Infections: Nuancing the Use of Antibiotics
Marin Hristos Kollef, MD; Peter L. Salgo, MD; Andrew Shorr, MD; and Yoav Golan, MD, share insight on the appropriate approach to using antibiotics when treating pseudomonas infections at multiple levels of care.
What Can Physicians Do If Their Patient Declines Getting Tested for HIV?
Colleen Kelley, MD, stresses the importance of routinizing HIV testing and shares what physicians can do if their patient declines the option to get tested.
How Can Mobile Apps Be Used to Improve Patient Outcomes?
Debra Goff, PharmD, FCCP, explains how mobile apps are being used by health care providers to improve patient outcomes.
Cell Phones: Potential Vectors for <i>C. diff</i>?
Barley Chironda, RPN, CIC, infection control specialist at Clorox Healthcare, explains how cell phones and smart devices can potentially serve as a vector for C. diff.
Gram-Positive NIs: Nuancing Lipoglycopeptide Therapy
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); Jason Pogue, PharmD, BCPS-AQID; Andrew Shorr, MD; and Debra Goff, PharmD, FCCP, reflect on the caveats in lipoglycopeptide therapy for gram-positive nosocomial infections and emphasize that this is a different, not overarchingly effective, class of drugs.
When Can Clinicians Expect Long-Acting Injectable ART?
Joseph Eron, MD, discusses when clinicians may expect to have access to long-acting injectable ART and the different opportunities it offers for individuals with HIV.
Selecting Lipoglycopeptide Therapy for Gram-Positive NIs
Peter L. Salgo, MD; Sandy J. Estrada Lopez, PharmD, BCPS (AQID); and Debra Goff, PharmD, FCCP, share insight on selecting the appropriate agent in the setting of lipoglycopeptide therapy for gram-positive nosocomial infections regarding dosing, mechanisms of action, and patient populations.
Big advances in treatment can